New hope for swallowing: drug targets esophagus repair in rare disease

NCT ID NCT06101095

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 24 times

Summary

This study tests dupilumab, an injectable drug, in 69 adults with eosinophilic esophagitis (EoE), a condition that makes swallowing difficult due to inflammation and scarring in the esophagus. Participants receive either dupilumab or a placebo for 24 weeks, then all receive dupilumab for 2 more years. The goal is to see if the drug improves esophageal function and reduces long-term damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Borland Groover Clinic- Site Number : 8400016

Jacksonville, Florida, 32256, United States
Cleveland Clinic - Cleveland- Site Number : 8400009

Cleveland, Ohio, 44195, United States
Clinica de Alergia Martti Antila- Site Number : 0760001

Sorocaba, São Paulo, 18040-425, Brazil
Clínica Loema - Unidade I- Site Number : 0760007

Campinas, São Paulo, 13010-001, Brazil
GI Alliance - Glenview- Site Number : 8400012

Glenview, Illinois, 60026, United States
GI Alliance - Mansfield- Site Number : 8400017

Mansfield, Texas, 76063, United States
Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003

São Paulo, 01323-020, Brazil
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Illinois Gastroenterology Group- Site Number : 8400004

Gurnee, Illinois, 60031, United States
Investigational Site Number : 1240002

Montreal, Quebec, H4A 3T2, Canada
Investigational Site Number : 1240004

Vancouver, British Columbia, V6Z 2K5, Canada
Investigational Site Number : 1240006

Vancouver, British Columbia, V5Z 1M9, Canada
Investigational Site Number : 3760002

Haifa, 3109601, Israel
Investigational Site Number : 3760003

Tel Aviv, 6423906, Israel
Investigational Site Number : 3760004

Jerusalem, 9112001, Israel
Investigational Site Number : 3760005

Jerusalem, 9103102, Israel
Investigational Site Number : 3760006

Haifa, 3104802, Israel
Investigational Site Number : 7560001

Wetzikon, 8620, Switzerland
Investigational Site Number : 7560002

Zurich, 8091, Switzerland
Itaigara Memorial - Hospital Dia- Site Number : 0760005

Salvador, Estado de Bahia, 41825-010, Brazil
Mayo Clinic Hospital Rochester- Site Number : 8400008

Rochester, Minnesota, 55905, United States
Northwestern University- Site Number : 8400003

Chicago, Illinois, 60611, United States
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010

Philadelphia, Pennsylvania, 19104, United States
Private Practice - Dr. Martin Yudovich- Site Number : 8400015

Houston, Texas, 77087, United States
Treasure Valley Medical Research- Site Number : 8400018

Boise, Idaho, 83706, United States
United Gastroenterologists - Murrieta- Site Number : 8400001

Murrieta, California, 92563, United States
University of California San Francisco - Parnassus Heights- Site Number : 8400020

San Francisco, California, 94143, United States
University of Iowa- Site Number : 8400006

Iowa City, Iowa, 52242, United States
University of Massachusetts Chan Medical School- Site Number : 8400019

Worcester, Massachusetts, 01655, United States
University of North Carolina at Chapel Hill- Site Number : 8400007

Chapel Hill, North Carolina, 27514, United States

Conditions

Explore the condition pages connected to this study.

EOSINOPHILIC OESOPHAGITIS